Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00069277
Status:
COMPLETED
Last Update Posted:
2012-04-11
First Post:
2003-09-19
Brief Title:
Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
A Phase I Dose-Finding Study of E7389 Halichondrin B Analog Administered Once Every Three Weeks in Patients With Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The malignancies advanced solid tumors that have been chosen for evaluation of E7389 are those where E7389 has demonstrated significant pre-clinical anti-tumor activity both in vitro and in vivo The ultimate goal is to demonstrate the clinical activity of E7389 in the treatment of these and potentially other tumor types
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None